Ocugen Inc. Announces Near Completion of Enrollment for OCU400 Phase 3 Clinical Trial, Aiming for BLA Filing by Mid-2026

Reuters

2025/06/11

<a href="https://laohu8.com/S/OCGN">Ocugen</a> Inc. Announces Near Completion of Enrollment for OCU400 Phase 3 Clinical Trial, Aiming for BLA Filing by Mid-2026

Ocugen Inc., a biotechnology company specializing in gene therapies for blindness diseases, has announced progress in its clinical trials and upcoming presentations. The company is nearing the completion of enrollment for the OCU400 Phase 3 liMeliGhT clinical trial, with plans to file a Biologics License Application $(BLA.AU)$ by mid-2026. Additionally, Ocugen will present at the 2025 BIO International Convention, taking place from June 16-19 in Boston. During the convention, Ocugen's leadership will engage with potential partners and discuss its novel gene therapy platform. Dr. Shankar Musunuri, Chairman, CEO, and Co-founder, will present on June 16 and participate in panel discussions on June 17 and 18. Results from the clinical trials have not yet been presented and will be shared in the future.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ocugen Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9466785-en) on June 11, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2542589551"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2542589551\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2542589551?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-11 19:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2542589551","market":"us","top_or_hot":-1,"title":"Ocugen Inc. Announces Near Completion of Enrollment for OCU400 Phase 3 Clinical Trial, Aiming for BLA Filing by Mid-2026","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/OCGN\">Ocugen</a> Inc. Announces Near Completion of Enrollment for OCU400 Phase 3 Clinical Trial, Aiming for BLA Filing by Mid-2026\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Ocugen Inc., a biotechnology company specializing in gene therapies for blindness diseases, has announced progress in its clinical trials and upcoming presentations. The company is nearing the completion of enrollment for the OCU400 Phase 3 liMeliGhT clinical trial, with plans to file a Biologics License Application <a href=\"https://laohu8.com/S/BLA.AU\">$(BLA.AU)$</a> by mid-2026. Additionally, Ocugen will present at the 2025 BIO International Convention, taking place from June 16-19 in Boston. During the convention, Ocugen's leadership will engage with potential partners and discuss its novel gene therapy platform. Dr. Shankar Musunuri, Chairman, CEO, and Co-founder, will present on June 16 and participate in panel discussions on June 17 and 18. Results from the clinical trials have not yet been presented and will be shared in the future.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ocugen Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9466785-en) on June 11, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen Inc. Announces Near Completion of Enrollment for OCU400 Phase 3 Clinical Trial, Aiming for BLA Filing by Mid-2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen Inc. Announces Near Completion of Enrollment for OCU400 Phase 3 Clinical Trial, Aiming for BLA Filing by Mid-2026\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-06-11 19:31</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/OCGN\">Ocugen</a> Inc. Announces Near Completion of Enrollment for OCU400 Phase 3 Clinical Trial, Aiming for BLA Filing by Mid-2026\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Ocugen Inc., a biotechnology company specializing in gene therapies for blindness diseases, has announced progress in its clinical trials and upcoming presentations. The company is nearing the completion of enrollment for the OCU400 Phase 3 liMeliGhT clinical trial, with plans to file a Biologics License Application <a href=\"https://laohu8.com/S/BLA.AU\">$(BLA.AU)$</a> by mid-2026. Additionally, Ocugen will present at the 2025 BIO International Convention, taking place from June 16-19 in Boston. During the convention, Ocugen's leadership will engage with potential partners and discuss its novel gene therapy platform. Dr. Shankar Musunuri, Chairman, CEO, and Co-founder, will present on June 16 and participate in panel discussions on June 17 and 18. Results from the clinical trials have not yet been presented and will be shared in the future.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ocugen Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9466785-en) on June 11, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4563","symbol_name":"昨日強勢股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250611:nNDL8wMmzq:1","article_id":"2542589551","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2542589551","pubTimestamp":1749641460,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Ocugen Inc., a biotechnology company specializing in gene therapies for blindness diseases, has announced progress in its clinical trials and upcoming presentations. The company is nearing the completion of enrollment for the OCU400 Phase 3 liMeliGhT clinical trial, with plans to file a Biologics License Application  by mid-2026. Additionally, Ocugen will present at the 2025 BIO International Convention, taking place from June 16-19 in Boston. During the convention, Ocugen's leadership will engage with potential partners and discuss its novel gene therapy platform. Dr. Shankar Musunuri, Chairman, CEO, and Co-founder, will present on June 16 and participate in panel discussions on June 17 and 18. Results from the clinical trials have not yet been presented and will be shared in the future.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4563":"昨日强势股","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","NDAQ":"纳斯达克OMX交易所","BK4139":"生物科技","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","OCGN":"Ocugen","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4568":"美国抗疫概念","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4112":"金融交易所和数据"},"translate_title":"Ocugen Inc.宣布OCU400 3期临床试验的招募即将完成，目标是在2026年中期提交BLA","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OCGN":0.9,"NDAQ":0.9},"content_text":"Ocugen Inc. Announces Near Completion of Enrollment for OCU400 Phase 3 Clinical Trial, Aiming for BLA Filing by Mid-2026\n    \n\n        Ocugen Inc., a biotechnology company specializing in gene therapies for blindness diseases, has announced progress in its clinical trials and upcoming presentations. The company is nearing the completion of enrollment for the OCU400 Phase 3 liMeliGhT clinical trial, with plans to file a Biologics License Application $(BLA.AU)$ by mid-2026. Additionally, Ocugen will present at the 2025 BIO International Convention, taking place from June 16-19 in Boston. During the convention, Ocugen's leadership will engage with potential partners and discuss its novel gene therapy platform. Dr. Shankar Musunuri, Chairman, CEO, and Co-founder, will present on June 16 and participate in panel discussions on June 17 and 18. Results from the clinical trials have not yet been presented and will be shared in the future.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ocugen Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9466785-en) on June 11, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}